ライフサイエンスコーパス: Calmette

1 Bacille Calmette Guerin-vaccinated children were more likely to

2 Bacille Calmette-Guerin (BCG) is an attenuated strain of Mycobac

3 Bacille Calmette-Guerin (BCG) vaccination has been suggested to

4 Bacille Calmette-Guerin (BCG) vaccination induces a marked incre

5 Bacille Calmette-Guerin (BCG) vaccination remains a cornerstone

6 Bacille Calmette-Guerin (BCG), an attenuated strain of Mycobacte

7 Bacille Calmette-Guerin is the most effective therapy for carcin

8 Bacille Calmette-Guerin vaccination, tuberculosis prevalence in

9 n December 2013 and January 2016, 36 bacille Calmette-Guerin-vaccinated, healthy UK adults were rando

10 e show in this article that although bacille Calmette-Guerin controlled M. tuberculosis growth for 7

11 odeficiency virus (HIV)-infected and bacille Calmette-Guerin (BCG)-immunized adults with CD4 cell cou

12 medical illness, isoniazid use, and bacille Calmette-Guerin strain did not substantially affect vacc

13 y to nontuberculous mycobacteria and bacille Calmette-Guerin vaccination may account for a proportion

14 n rates and responses to tetanus and Bacille Calmette-Guerin vaccines among HEU and HUU vaccinees.

15 rain of Mycobacterium bovis known as bacille Calmette-Guerin (BCG) has been widely used as a vaccine

16 Certain vaccines, such as Bacille Calmette-Guerin (BCG), have nonspecific effects, which m

17 rologous effects of vaccines such as bacille Calmette-Guerin (BCG), the licensed TB vaccine.

18 Live attenuated Bacille Calmette-Guerin (BCG) bacillus is the only licensed vacc

19 erium tuberculosis vaccines to boost bacille Calmette-Guerin or for those who cannot be immunized wit

20 osis Ag 85A (M.85A), strongly boosts bacille Calmette-Guerin (BCG)-induced Ag 85A specific CD4(+) and

21 strict growth of Mycobacterium bovis bacille Calmette Guerin and Mycobacterium tuberculosis was impai

22 ollow the migration of live M. bovis Bacille Calmette-Guerin (BCG) and to observe interactions with e

23 Vaccination with Mycobacterium bovis bacille Calmette-Guerin (BCG) has variable efficacy in preventin

24 ells specific to Mycobacterium bovis bacille Calmette-Guerin (BCG) in the lungs, and the IFN-gamma CD

25 terium avium and Mycobacterium bovis Bacille Calmette-Guerin (BCG) in vitro.

26 expansion during Mycobacterium bovis Bacille Calmette-Guerin (BCG) infection and a clear memory-type

27 ls responding to Mycobacterium bovis bacille Calmette-Guerin (BCG) infection and disrupt granuloma fo

28 enriched diet on Mycobacterium bovis bacille Calmette-Guerin (BCG) infection.

29 d vaccination at birth with M. bovis bacille Calmette-Guerin (BCG) is widely used.

30 sing intradermal Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccination as a surrogate for M.

31 conferred by the Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccine are multifaceted and poorl

32 Because Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccine can confer protection agai

33 um smegmatis and Mycobacterium bovis bacille Calmette-Guerin (BCG), which respectively induce high an

34 ly infected with Mycobacterium bovis bacille Calmette-Guerin (BCG).

35 but not the vaccine strain M. bovis bacille Calmette-Guerin (BCG).

36 activity against Mycobacterium bovis bacille Calmette-Guerin and virulent M. tuberculosis.

37 that exposure of Mycobacterium bovis Bacille Calmette-Guerin or Mycobacterium marinum to thiacetazone

38 Infection with Mycobacterium bovis bacille Calmette-Guerin resulted in approximately 10-fold-higher

39 tuberculosis and Mycobacterium bovis bacille Calmette-Guerin similarly home to established granulomas

40 enge compared with standard M. bovis bacille Calmette-Guerin vaccination.

41 tuberculosis and Mycobacterium bovis bacille Calmette-Guerin, release MVs when growing in both liquid

42 enuated form of Mycobacterium bovis, bacille Calmette-Guerin (BCG).

43 detect antibody responses induced by bacille Calmette-Guerin (BCG) vaccination and active tuberculosi

44 thin hepatic granulomas triggered by Bacille Calmette-Guerin or Mycobacterium tuberculosis.

45 days) than mice infected with either bacille Calmette-Guerin (BCG) vaccine or virulent M. tuberculosi

46 l Ags in the context of experimental bacille Calmette-Guerin (BCG) vaccination, Ag-specific T cell re

47 icial bladder cancer who have failed bacille Calmette-Guerin.

48 ries was 2.3 weeks (IQR 1.4-4.6) for bacille Calmette-Guerin (BCG); 2.4 weeks (1.2-3.3) for diphtheri

49 an effective combination therapy for bacille Calmette-Guerin failures.

50 roposed as a second-line therapy for bacille Calmette-Guerin failures.

51 the standard-of-care immunotherapy, bacille Calmette-Guerin (BCG), constitute a challenging patient

52 une correlates of TB disease risk in Bacille Calmette-Guerin (BCG) immunized infants from the MVA85A

53 secreting T cells when used alone in bacille Calmette-Guerin (BCG)-naive healthy volunteers.

54 bovis bloodstream infection (BSI) in bacille Calmette-Guerin (BCG)-vaccinated children with human imm

55 ibit mycobacterial growth, including Bacille Calmette-Guerin (BCG) and Mycobacterium tuberculosis (MT

56 Intravesical bacille Calmette-Guerin (including a maintenance regimen) should

57 of 10 of these 19 patients with live bacille Calmette-Guerin.

58 The variable efficacy of Bacille Calmette Guerin (BCG) vaccination against tuberculosis h

59 Use of bacille Calmette-Guerin (BCG) as a surrogate for human Mycobacte

60 hown that systemic administration of Bacille Calmette-Guerin (BCG) or beta-glucan reprograms HSCs in

61 RAs in individuals with a history of Bacille Calmette-Guerin (BCG) vaccination after infancy or with

62 Approximately 100 million doses of bacille Calmette-Guerin (BCG) vaccine are given each year to pro

63 nd pyrazinamide restricted growth of bacille Calmette-Guerin but not wild-type Mycobacterium bovis, w

64 e, M72/AS01, in a phase IIa trial of bacille Calmette-Guerin-vaccinated, HIV-uninfected, and Mycobact

65 th environmental mycobacteria and/or bacille Calmette-Guerin (BCG) vaccination compromise the estimat

66 e-promastigote vaccine cocktail plus bacille Calmette-Guerin (BCG) adjuvant significantly reduced the

67 ell melanoma vaccine, Canvaxin, plus Bacille Calmette-Guerin (BCG) versus placebo plus BCG.

68 tion involves the use of recombinant bacille Calmette-Guerin (rBCG) overexpressing protective TB anti

69 Failure to replace Bacille Calmette-Guerin vaccines with efficacious anti-tuberculo

70 ection in Mycobacterium bovis strain bacille Calmette-Guerin (BCG)-induced granulomas using an immuno

71 cterium bovis-derived vaccine strain bacille Calmette-Guerin (BCG).

72 n sharp contrast, the vaccine strain bacille Calmette-Guerin as well as RD-1 and ESAT-6 mutants of H3

73 Here we show that bacille Calmette-Guerin (BCG) vaccination in healthy volunteers

74 We have previously established that bacille Calmette-Guerin (BCG), an attenuated form of Mycobacteri

75 erculosis every year even though the bacille Calmette Guerin (BCG) vaccine has been available for mor

76 Policies regarding the use of the Bacille Calmette-Guerin (BCG) vaccine for tuberculosis vary grea

77 stence of therapeutic agents and the bacille Calmette-Guerin (BCG) vaccine have not significantly aff

78 r specificity in those receiving the bacille Calmette-Guerin vaccine and poor sensitivity in individu

79 Research into the bacille Calmette-Guerin vaccine demonstrated the importance of c

80 The bacille Calmette-Guerin vaccine provides very efficient protecti

81 The failure of the bacille Calmette-Guerin vaccine, synergy between AIDS and TB, an

82 ected macaques previously exposed to bacille Calmette-Guerin (BCG) were reinfected with BCG, were tre

83 The addition of interferon to bacille Calmette-Guerin has proven to be an effective combinatio

84 and existing ones improved to treat bacille Calmette-Guerin-refractory superficial bladder cancer.

85 iable efficacy of the currently used bacille Calmette-Guerin vaccine.

86 mycobacterial challenge model, using bacille Calmette-Guerin (BCG) as a surrogate for a Mycobacterium

87 The tuberculosis (TB) vaccine bacille Calmette-Guerin (BCG) is a live attenuated organism, but

88 the partially efficacious TB vaccine bacille Calmette-Guerin (BCG) remain poorly defined.

89 live attenuated tuberculosis vaccine bacille Calmette-Guerin (BCG).

90 intravesical agent in patients with bacille Calmette-Guerin (BCG) -refractory transitional cell carc

91 ho receive intravesical therapy with bacille Calmette-Guerin should be considered for ongoing mainten

92 r those who cannot be immunized with bacille Calmette-Guerin.

93 ous, DNP-modified vaccine mixed with bacille Calmette-Guerin.

94 y infection with Mycobacterium bovis Bacille-Calmette-Guerin (BCG).

95 such as M. tuberculosis and M. bovis Bacille-Calmette-Guerin.

96 exposure to M. tuberculosis from the Bacille-Calmette-Guerin vaccine strain, they currently lack the

97 had or had not been vaccinated with Bacille-Calmette Guerin (BCG).

98 Bacillus Calmette-Guerin (BCG) has been used for vaccination agai

99 Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer i

100 Bacillus Calmette-Guerin (BCG) is the only licensed vaccine for t

101 Bacillus Calmette-Guerin (BCG) osteitis was more common in Finlan

102 Bacillus Calmette-Guerin (BCG) seems to have beneficial nonspecif

103 Bacillus Calmette-Guerin (BCG) vaccination induces variable prote

104 Bacillus Calmette-Guerin (BCG) vaccine is the most widely adminis

105 Bacillus Calmette-Guerin (BCG) vaccine is widely used for the pre

106 Bacillus Calmette-Guerin (BCG), the antituberculosis vaccine, loc

107 Bacillus Calmette-Guerin (BCG), the only licensed TB vaccine, pro

108 Bacillus Calmette-Guerin (BCG), the tuberculosis vaccine, is an a

109 Bacillus Calmette-Guerin instillation after removal of the tumor

110 Bacillus Calmette-Guerin therapy fails in >50% of cases, and seco

111 Bacillus Calmette-Guerin-induced production of the proinflammator

112 ements, other dietary approaches, a Bacillus Calmette-Guerin trial in 1976, molecular-targeted agents

113 dder cancer (NMIBC) recurrent after bacillus Calmette-Guerin therapy is complex and further complicat

114 Multivariate analyses examined age, bacillus Calmette-Guerin (BCG) vaccination status, and sex as pre

115 Although Bacillus Calmette-Guerin (BCG) intravesical therapy is a standard

116 Although Bacillus Calmette-Guerin (BCG) vaccines against tuberculosis have

117 oth tuberculosis (TB) infection and bacillus Calmette Guerin (BCG) vaccination.

118 y of interventions, such as IPT and bacillus Calmette-Guerin (BCG) vaccination for preventing TB dise

119 ium tuberculosis (strain H37Rv) and bacillus Calmette-Guerin (BCG) vaccine inhibit phagosome maturati

120 ate tuberculosis susceptibility and bacillus Calmette-Guerin (BCG)-induced immunity are mostly unknow

121 that Mycobacterium tuberculosis and bacillus Calmette-Guerin infections of macaques induced expressio

122 status of index cases, the age and bacillus Calmette-Guerin vaccination status of contacts, and stud

123 r the bacteria Escherichia coli and bacillus Calmette-Guerin, which increased other DC subsets.

124 Immunomodulators such as Bacillus Calmette-Guerin and interferon are clinically active in

125 ted TLR ligands or bacteria such as bacillus Calmette-Guerin increases antitumor immune responses and

126 was also observed during S. aureus, bacillus Calmette-Guerin (BCG), or E. coli infection, as well as

127 The only vaccine available, Bacillus Calmette-Guerin (BCG), has been used since its inception

128 on after stimulation with live BCG (Bacillus Calmette-Guerin), and a second locus on chromosome regio

129 The only available vaccine, BCG (Bacillus Calmette-Guerin), is given intradermally and has variabl

130 e estimated the association between bacillus Calmette-Guerin (BCG) vaccination and childhood asthma i

131 culosis (TB) vaccine trial to boost bacillus Calmette-Guerin-mediated anti-TB immunity despite the in

132 for the derivation of the M. bovis bacillus Calmette and Guerin (BCG) vaccine strain selected for an

133 n combined with Mycobacterium bovis bacillus Calmette Guerin (BCG) represents a potential strategy fo

134 ed 3,290 mutant Mycobacterium bovis bacillus Calmette Guerin (BCG) strains to identify genes that dec

135 munization with Mycobacterium bovis bacillus Calmette-Guerin (BCG) administered subcutaneously.

136 nes, based upon Mycobacterium bovis bacillus Calmette-Guerin (BCG) all interfere with the action of t

137 accination with Mycobacterium bovis bacillus Calmette-Guerin (BCG) alone or as a BCG prime/Mtb72F-boo

138 vaccinated with Mycobacterium bovis bacillus Calmette-Guerin (BCG) and were then challenged with viru

139 en expressed in Mycobacterium bovis bacillus Calmette-Guerin (BCG) but not when all seven phosphoryla

140 wall lipids of Mycobacterium bovis bacillus Calmette-Guerin (BCG) by coating the lipids onto 90-micr

141 ministration of Mycobacterium bovis bacillus Calmette-Guerin (BCG) continues to be a successful immun

142 Using Mycobacterium bovis bacillus Calmette-Guerin (BCG) cultures and TB-positive sputum sa

143 In contrast, the vaccine M. bovis bacillus Calmette-Guerin (BCG) does not stimulate MMP-1 secretion

144 cobacteria since avirulent M. bovis bacillus Calmette-Guerin (BCG) fails to trigger significant expre

145 Mycobacterium bovis bacillus Calmette-Guerin (BCG) has been used to treat bladder can

146 lular growth of Mycobacterium bovis bacillus Calmette-Guerin (BCG) in human macrophages.

147 uberculosis and Mycobacterium bovis bacillus Calmette-Guerin (BCG) induce potent expansions of human

148 okine following Mycobacterium bovis bacillus Calmette-Guerin (BCG) infection.

149 vaccinated with Mycobacterium bovis bacillus Calmette-Guerin (BCG) nor tuberculin skin test (TST) pos

150 ses to M. tuberculosis and M. bovis bacillus Calmette-Guerin (BCG) Pasteur in vivo and in vitro.

151 the control of Mycobacterium bovis bacillus Calmette-Guerin (BCG) pleural infection in a murine mode

152 ected with live Mycobacterium bovis Bacillus Calmette-Guerin (BCG) produced large amounts of CXCL1 an

153 accination with Mycobacterium bovis bacillus Calmette-Guerin (BCG) remains the only prophylactic vacc

154 protocols using Mycobacterium bovis bacillus Calmette-Guerin (BCG) to prime and modified vaccinia vir

155 the failure of Mycobacterium bovis bacillus Calmette-Guerin (BCG) to protect against disease, new va

156 Mycobacterium bovis Bacillus Calmette-Guerin (BCG) use in the treatment of bladder ca

157 Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccination is efficacious for new

158 dies induced by Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccination to protect against myc

159 The Mycobacterium bovis Bacillus Calmette-Guerin (BCG) vaccine is administered parenteral

160 eover, improved Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccine-induced protection was los

161 osis (Mtb), and Mycobacterium bovis bacillus Calmette-Guerin (BCG) were studied for their ability to

162 vaccine strain Mycobacterium bovis bacillus Calmette-Guerin (BCG), and it is hypothesized that these

163 ulosis vaccine, Mycobacterium bovis bacillus Calmette-Guerin (BCG), is contraindicated for immunocomp

164 e only vaccine, Mycobacterium bovis bacillus Calmette-Guerin (BCG), is largely ineffective, and ways

165 r macrophages infected with M bovis Bacillus Calmette-Guerin (BCG), M phlei, M avium 2151-rough, and

166 infection with Mycobacterium bovis bacillus Calmette-Guerin (BCG), peaking by days 14-21 posttreatme

167 Mycobacterium bovis bacillus Calmette-Guerin (BCG), the only TB vaccine in common use

168 Tmt ortholog in Mycobacterium bovis Bacillus Calmette-Guerin (BCG), we show for the first time that a

169 Th1 immunity is Mycobacterium bovis bacillus Calmette-Guerin (BCG), which has been used in newborns f

170 emonstrate that Mycobacterium bovis bacillus Calmette-Guerin (BCG)-mediated TLR2 signaling-induced iN

171 istance against Mycobacterium bovis bacillus Calmette-Guerin (BCG).

172 Mycoplasma and Mycobacterium bovis Bacillus Calmette-Guerin (BCG).

173 live attenuated Mycobacterium bovis bacillus Calmette-Guerin (BCG).

174 infection with Mycobacterium bovis bacillus Calmette-Guerin (BCG).

175 smegmatis) and Mycobacterium bovis Bacillus Calmette-Guerin (BCG).

176 h1 responses to Mycobacterium bovis bacillus Calmette-Guerin (BCG).

177 ven heat-killed Mycobacterium bovis bacillus Calmette-Guerin (HK-BCG) i.p. did not release PGE(2).

178 (along with the attenuated M. bovis bacillus Calmette-Guerin [BCG]), and Mycobacterium microti; incre

179 In this report, Mycobacterium bovis bacillus Calmette-Guerin and M. tuberculosis H37Ra were used as m

180 ed in increased Mycobacterium bovis bacillus Calmette-Guerin and Mycobacterium tuberculosis H(37)R(v)

181 infection with Mycobacterium bovis bacillus Calmette-Guerin and Mycobacterium tuberculosis.

182 accination with Mycobacterium bovis bacillus Calmette-Guerin compared with control mice after infecti

183 nduced cross processing of M. bovis bacillus Calmette-Guerin expressing OVA could be circumvented by

184 hanced cross processing of M. bovis bacillus Calmette-Guerin expressing OVA, bypassing the inhibition

185 le infection by Mycobacterium bovis bacillus Calmette-Guerin failed to induce IRF-1 expression and ha

186 infection with Mycobacterium bovis bacillus Calmette-Guerin in mice.

187 the attenuated Mycobacterium bovis bacillus Calmette-Guerin induces less PPARgamma and preferentiall

188 Following Mycobacterium bovis bacillus Calmette-Guerin infection and costimulation with IFN-gam

189 t that M. tuberculosis and M. bovis bacillus Calmette-Guerin infection down-regulated the expression

190 in response to Mycobacterium bovis bacillus Calmette-Guerin infections.

191 d nonpathogenic Mycobacterium bovis bacillus Calmette-Guerin intracellular survival, downregulated an

192 enuated vaccine Mycobacterium bovis bacillus Calmette-Guerin or the adoptive transfer of mycobacteria

193 ted with viable Mycobacterium bovis bacillus Calmette-Guerin or TLR ligands.

194 ith recombinant Mycobacterium bovis bacillus Calmette-Guerin overexpressing the 30-kDa antigen, C3HeB

195 ported that M. marinum and M. bovis bacillus Calmette-Guerin produce a type of spore known as an endo

196 izing mice with Mycobacterium bovis bacillus Calmette-Guerin to augment host immunity before infectio

197 ells induced by Mycobacterium bovis bacillus Calmette-Guerin vaccination.

198 obacter pylori, Mycobacterium bovis bacillus Calmette-Guerin, and Citrobacter rodentium and of tumor

199 by bcg_1279c in Mycobacterium bovis bacillus Calmette-Guerin, plays an important role in mycobacteria

200 Mycobacterium bovis bacillus Calmette-Guerin, the only vaccine available against tube

201 ition of M. tuberculosis var. bovis Bacillus Calmette-Guerin-induced p38 MAPK activity caused a marke

202 isolated from the serum of M. bovis bacillus Calmette-Guerin-infected mice could also stimulate macro

203 M. bovis bacillus Calmette-Guerin-primed sanroque T cells transferred into

204 r infected with Mycobacterium bovis bacillus Calmette-Guerin.

205 vaccine strain Mycobacterium bovis bacillus Calmette-Guerin.

206 vaccine strain Mycobacterium bovis bacillus Calmette-Guerin.

207 bacterial activity against M. bovis bacillus Calmette-Guerin.

208 cus aureus, and Mycobacterium bovis bacillus Calmette-Guerin.

209 sis; the vaccine strain of M. bovis Bacillus Calmette-Guerin; and M. kansasii to demonstrate detectio

210 nd CD8+ T cell responses induced by bacillus Calmette-Guerin and a recombinant subunit protein vaccin

211 Vaccinations studied comprised Bacillus Calmette-Guerin (BCG) vaccine, Triple vaccine, Hepatitis

212 with the phosphoantigen-containing bacillus Calmette-Guerin (BCG) vaccine.

213 bject 1 presented with disseminated Bacillus Calmette-Guerin infection and oligoclonal T cells with n

214 apoptosis of CD4(+) T cells during bacillus Calmette-Guerin (BCG) infection of mice.

215 or cells producing IFN-gamma during bacillus Calmette-Guerin (BCG) vaccination and subsequent M. tube

216 ighly induced in macrophages during bacillus Calmette-Guerin infection.

217 fforts toward developing agents for bacillus Calmette-Guerin-refractory superficial bladder cancer co

218 es in the development of agents for bacillus Calmette-Guerin-refractory superficial bladder cancer.

219 he underwent cystoprostatectomy for bacillus Calmette-Guerin-refractory, high-grade noninvasive UC.

220 differentiation of Th17 cells from bacillus Calmette-Guerin-challenged (BCG-challenged) lung CD4+ T

221 e observed in livers and lungs from bacillus Calmette-Guerin-infected humanized mice but not in nonhu

222 4 expression by CD4(+) T cells from bacillus Calmette-Guerin-vaccinated mice and show that high-quali

223 Furthermore, bacillus Calmette-Guerin-vaccinated IFN-gamma-deficient mice exhi

224 is Ags Ag85A, Ag85B, and TB10.4, in bacillus Calmette-Guerin (BCG)-primed or unprimed rhesus macaques

225 tifs within AM and its functions in bacillus Calmette-Guerin vaccination and/or in controlled (latent

226 th factor Vegf-c is up-regulated in Bacillus Calmette-Guerin- and Mycobacterium tuberculosis-induced

227 udy to determine the feasibility in Bacillus Calmette-Guerin-naive patients.

228 In bacillus Calmette-Guerin-vaccinated subjects and those with laten

229 target, also lowered intracellular Bacillus Calmette-Guerin levels in mammary epithelial cancer MCF-

230 for patients who fail intravesical bacillus Calmette-Guerin (BCG) for nonmuscle invasive bladder can

231 r cancer refractory to intravesical bacillus Calmette-Guerin (BCG) therapy and refusing a cystectomy

232 patients according to intravesical Bacillus Calmette-Guerin (BCG) treatment status: no BCG, inductio

233 ta supports the use of intravesical Bacillus Calmette-Guerin (including a maintenance regimen) for th

234 ata support the use of intravesical bacillus Calmette-Guerin (including a maintenance regimen) for th

235 rastriatal injection of heat-killed bacillus Calmette-Guerin (BCG) and subsequent activation using an

236 safety, and immunogenicity of live bacillus Calmette-Guerin (BCG) in a lung-oriented controlled huma

237 th lymphadenitis caused by the live Bacillus Calmette-Guerin (BCG) vaccine.

238 Mtb- specific antigens and live bacillus Calmette-Guerin (BCG) were used as stimuli, with direct

239 n response to stimulation with live bacillus Calmette-Guerin (BCG; LOD score, 3.81; P = 1.40 x 10(-5)

240 Although maintenance bacillus Calmette-Guerin (BCG) for at least 1 year has been recom

241 ts include intravesical maintenance Bacillus Calmette-Guerin (mBCG) and radical cystectomy (RC).

242 e considered the childhood measles, bacillus Calmette-Guerin, diphtheria-pertussis-tetanus, polio, an

243 gative association between national bacillus Calmette-Guerin (BCG) vaccination policy and the prevale

244 lomas from M. tuberculosis- but not bacillus Calmette-Guerin-infected humanized mice.

245 r a single dose (1 x 10(5) CFUs) of bacillus Calmette-Guerin (BCG) or Mycobacterium vaccae via nasal

246 ion showed that old age, absence of bacillus Calmette-Guerin (BCG) scar, presence of donor-specific a

247 In Taiwan, the inoculation of Bacillus Calmette-Guerin (BCG) Tokyo-172 strain vaccine was postp

248 of PBMCs with the Moreau strain of bacillus Calmette-Guerin but not after infection with other strai

249 he primary attenuating mechanism of bacillus Calmette-Guerin is the loss of cytolytic activity mediat

250 H65 gave protection at the level of bacillus Calmette-Guerin, and the fusion protein exhibited high p

251 ciated carcinoma in situ, nonuse of bacillus Calmette-Guerin, tumor size > 3 cm, and older age; HRs f

252 Granulomas of bacillus Calmette-Guerin-infected humanized mice administered wit

253 uch as intravesical instillation of Bacillus Calmette-Guerin.

254 are more effective than the present bacillus Calmette-Guerin (BCG) vaccine.

255 and TST (with adjustment for prior bacillus Calmette-Guerin [BCG] vaccination).Measurements and Main

256 us pneumoniae, Helicobacter pylori, bacillus Calmette-Guerin, and Mycobacterium tuberculosis) in a mu

257 We generated a recombinant Bacillus Calmette-Guerin ([BCG] BCG-disA-OE) that overexpresses t

258 tion, immunization with recombinant bacillus Calmette-Guerin (BCG) expressing RSV nucleoprotein preve

259 CV candidates, based on recombinant bacillus Calmette-Guerin (BCG), attenuated Mycobacterium tubercul

260 fore and after primary or secondary bacillus Calmette-Guerin (BCG) vaccination were assessed for Ab r

261 parison of the efficacy of standard bacillus Calmette-Guerin vaccination as well as novel TB vaccines

262 duced by Mycobacterium bovis strain bacillus Calmette-Guerin (BCG) in mice.

263 that a more effective vaccine than bacillus Calmette-Guerin is urgently needed.

264 In this study, we found that bacillus Calmette-Guerin (BCG) and viable M. tuberculosis as well

265 Studies have suggested that Bacillus Calmette-Guerin (BCG) vaccination may reduce the risk of

266 Evidence suggests that bacillus Calmette-Guerin is the most effective intravesical thera

267 The Bacillus Calmette - Guerin (BCG) vaccine provides a critical but

268 The bacillus Calmette-Guerin (BCG) strain of Mycobacterium bovis is u

269 The Bacillus Calmette-Guerin (BCG) vaccine provides protection agains

270 immunotherapy instillation with the bacillus Calmette-Guerin (BCG) vaccine.

271 atients had previously received the bacillus Calmette-Guerin (BCG) vaccine; among this vaccinated gro

272 Mycobacterium tuberculosis and the bacillus Calmette-Guerin can be tracked directly in the lungs of

273 among persons who had received the Bacillus Calmette-Guerin vaccine in households with and without a

274 ate) or placebo together with their Bacillus Calmette-Guerin vaccination.

275 er (NMIBC) are either refractory to bacillus Calmette-Guerin (BCG) treatment or may experience diseas

276 ulent M. tuberculosis comparable to bacillus Calmette-Guerin immunization.

277 n mediating Th1 immune responses to Bacillus Calmette-Guerin infection in vivo.

278 ated as alternatives to traditional Bacillus Calmette-Guerin needles and syringes for the administrat

279 lable vaccine against tuberculosis, bacillus Calmette Guerin (BCG), has traditionally been viewed not

280 mans as a vaccine for tuberculosis, Bacillus Calmette-Guerin (BCG) has been suggested as a possible a

281 nrolled 98 healthy, HIV-uninfected, bacillus Calmette-Guerin-vaccinated, South African adults.

282 ccines revealed that currently used bacillus Calmette-Guerin strains vary in their ability to affect

283 ty, by the antituberculosis vaccine bacillus Calmette-Guerin (BCG) contributes to protection against

284 KGROUNDThe antituberculosis vaccine bacillus Calmette-Guerin (BCG) reduces overall infant mortality.

285 cy of the only licensed TB vaccine, Bacillus Calmette-Guerin (BCG) against pulmonary TB.

286 w the current tuberculosis vaccine, bacillus Calmette-Guerin (BCG), impacts early immunity is poorly

287 cted a novel breast cancer vaccine, Bacillus Calmette-Guerin (BCG)-hIL2MUC1, that consists of BCG and

288 While bacillus Calmette-Guerin vaccination plays an important role in r

289 the population of patients for whom bacillus Calmette-Guerin (BCG) has failed, the type of failure (B

290 When monkeys were immunized with bacillus Calmette-Guerin (BCG) and then boosted with Mtb72F in AS

291 n (KLH) as a carrier and given with Bacillus Calmette-Guerin (BCG) as an adjuvant, elicited HMW-MAA-s

292 Vaccination with Bacillus Calmette-Guerin (BCG) has been shown to reduce the sever

293 apy (IPT) before revaccination with bacillus Calmette-Guerin (BCG) in healthy, tuberculin skin test-p

294 negative IGRAs was associated with bacillus Calmette-Guerin (BCG) vaccination (odds ratio: 25.1 [95%

295 n a mouse model of vaccination with bacillus Calmette-Guerin (BCG), followed by challenge with virule

296 and vaccination, in particular with Bacillus Calmette-Guerin (BCG), remain the main strategies to con

297 s comparable to those achieved with bacillus Calmette-Guerin vaccination.

298 The Danish Calmette Study is a multicenter randomized trial conduct

299 The Danish Calmette Study was conducted 2012-2015.

300 radiated autologous tumor cells admixed with Calmette-Guerin bacillus.